Ibio (IBIO) AI Stock Analysis

• Market Cap: $55.30M
• Dividend Yield: N/A
• Average Volume (3M): 667.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: 650.00%
• EPS Growth: 89.72%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 74
• Industry: Biotechnology
• EPS (TTM): -2.70
• Shares Outstanding: 9,874,676
• 10 Day Avg. Volume: 1,403,085
• 30 Day Avg. Volume: 667,097
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 147.46
• Price to Cash Flow (P/CF): -3.50
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $6.00
• Price Target Upside: 7.14% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

IBio's overall score reflects a mix of significant financial challenges, balanced by strong technical momentum. The company's negative earnings and cash flow are major concerns, but recent strategic initiatives and positive technical indicators provide some optimism. Valuation remains a hurdle due to negative profitability metrics.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc. is a biotechnology company that focuses on developing plant-based biologics for the biopharmaceutical market. The company operates primarily in the sectors of biopharmaceutical development and manufacturing, utilizing its proprietary FastPharming System to produce vaccines and therapeutic proteins. iBio aims to provide more efficient and cost-effective solutions for biologics production, targeting areas such as oncology, fibrosis, and infectious diseases.

How the Company Makes Money

iBio generates revenue through its biopharmaceutical development initiatives and contract manufacturing services. The company's primary revenue streams include licensing agreements, where it licenses its FastPharming technology to other organizations, and contract development and manufacturing services, where it produces plant-based biologics for clients. Additionally, iBio may engage in strategic partnerships and collaborations to enhance its development pipeline and expand its market reach. The company also seeks to advance its proprietary therapeutic candidates, which, upon successful development and commercialization, could provide additional revenue through sales or out-licensing deals.

Ibio Financial Statement Overview

Summary

IBio is facing substantial financial challenges, with negative net income and EBIT margin, indicating a lack of profitability. Revenue is declining, and despite some balance sheet stability, the overall financial health is weak, posing significant risks for investors.

Income Statement

IBio is experiencing significant challenges in its income statement. The company has a negative net income and EBIT margin, indicating operational inefficiencies and a lack of profitability. Revenue has been declining over the past few years, exacerbating the situation. The gross profit margin is positive for the TTM, but the net profit margin is deeply negative, signaling high costs relative to revenue.

Balance Sheet

The balance sheet shows some stability, with a reasonable debt-to-equity ratio and a positive equity ratio. However, the company's return on equity is negative due to sustained net losses, which is a concern for potential investors. The reduction in stockholders' equity over time also highlights financial strain.

Cash Flow

IBio's cash flow statements indicate a negative free cash flow, which suggests the company is burning cash at a high rate. Operating cash flow is also negative, highlighting difficulties in generating cash from core operations. The growth rate of free cash flow remains negative, reflecting ongoing financial challenges.

Breakdown
TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement		Total Revenue
375.00K	225.00K	0.00	2.38M	2.37M	1.64M
	Gross Profit
787.00K	225.00K	-1.11M	2.17M	909.00K	935.00K
	EBIT
-15.51M	-16.63M	-29.31M	-49.69M	-31.11M	-14.00M
	EBITDA
-12.84M	-14.02M	-28.12M	-25.72M	-18.34M	-11.74M
	Net Income Common Stockholders
-19.30M	-24.91M	-29.31M	-51.01M	-23.26M	-18.91M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.22M	14.21M	4.30M	33.52M	96.97M	55.11M
	Total Assets
50.15M	28.73M	41.21M	99.41M	146.97M	94.19M
	Total Debt
17.33M	4.46M	17.07M	27.79M	32.72M	32.91M
	Net Debt
11.12M	-9.75M	12.77M	5.12M	-44.68M	-22.20M
	Total Liabilities
25.29M	7.41M	25.83M	35.92M	38.40M	37.58M
	Stockholders Equity
24.86M	21.32M	15.38M	63.48M	108.58M	56.62M
Cash Flow		Free Cash Flow
-16.30M	-18.76M	-36.17M	-49.11M	-35.23M	-14.50M
	Operating Cash Flow
-16.09M	-18.55M	-30.44M	-37.48M	-30.06M	-13.35M
	Investing Cash Flow
1.57M	906.00K	7.01M	-5.13M	-26.48M	-1.15M
	Financing Cash Flow
17.70M	24.49M	2.30M	-6.13M	78.83M	65.19M

Ibio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.60
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Positive. The current price of 5.6 is above the 20-day moving average (MA) of 4.40, above the 50-day MA of 3.44, and above the 200-day MA of 2.56, indicating a bullish trend. The MACD of 0.77 indicates Negative momentum. The RSI at 64.12 is Neutral, neither overbought nor oversold. The STOCH value of 75.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BCRX	55 Neutral	$1.64B	―	18.68%	―	36.00%	63.50%
VXRT	55 Neutral	$107.35M	―	-103.37%	―	303.27%	36.35%
IBIO	54 Neutral	$55.30M	―	-123.28%	―	650.00%	89.72%
XBIO	53 Neutral	$5.84M	―	-45.48%	―	7.15%	9.33%
Sector *	49 Neutral	$7.05B	0.34	-55.09%	2.46%	25.27%	-3.43%
NVAX	40 Underperform	$1.34B	―	30.06%	―	-30.65%	77.62%
INO	33 Underperform	$70.76M	―	-106.64%	―	-76.18%	40.70%

Ibio Corporate Events

iBio Announces Transfer to Nasdaq Capital Market

On February 19, 2025, iBio, Inc. announced its decision to transfer the listing of its common stock from NYSE American to the Nasdaq Capital Market. The trading on NYSE American will end on March 3, 2025, with Nasdaq trading commencing on March 4, 2025, under the same ticker symbol ‘IBIO.’ The company believes this move will enhance visibility, trading liquidity, and exposure to institutional investors, aligning with its strategy to join a community of leading biotech firms.

iBio Advances Antibody Development for Obesity Treatment

iBio, Inc. announced an update to its corporate presentation, highlighting the development of an antibody that inhibits Activin E, a therapeutic target for cardiometabolic disorders and obesity. Utilizing its patented machine-learning antibody engine, iBio aims to enhance its industry positioning by demonstrating strong preclinical results and advancing its pipeline for future clinical applications, potentially impacting stakeholders by offering innovative treatments for obesity and related conditions.

iBio Expands Pipeline with New Antibody Agreement

iBio, Inc. announced an exclusive agreement with AstralBio to license a long-acting anti-myostatin antibody, IBIO-600, designed for obesity and cardiometabolic disorders. This agreement involves an upfront payment of $750,000 in stock and potential milestone payments up to $28 million. The collaboration enables iBio to expand its treatment programs, leveraging its proprietary technology for developing a bispecific antibody targeting myostatin/activin A, with the aim of entering clinical trials in 2026. The initiative reflects iBio’s strategy to enhance its pipeline with advanced therapeutics that promote weight loss while preserving muscle mass.